Trifluridine adverse reactions: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi (talk | contribs) mNo edit summary |
Gerald Chi (talk | contribs) |
||
| Line 4: | Line 4: | ||
==Adverse Reactions== | ==Adverse Reactions== | ||
The most frequent adverse reactions reported during controlled clinical trials were mild, transient burning or stinging upon instillation (4.6%) and palpebral [[edema]] (2.8%). Other adverse reactions in decreasing order of reported frequency were superficial punctate keratopathy, epithelial keratopathy, hypersensitivity reaction, stromal edema, irritation, | The most frequent adverse reactions reported during controlled clinical trials were mild, transient burning or stinging upon instillation (4.6%) and palpebral [[edema]] (2.8%). Other adverse reactions in decreasing order of reported frequency were superficial punctate keratopathy, epithelial keratopathy, hypersensitivity reaction, stromal edema, irritation, keratitis sicca, [[hyperemia]], and increased intraocular pressure.<ref>{{Cite web | last = | first =|title = http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022211s000_sumr.pdf | url =http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022211s000_sumr.pdf | publisher = |date = | accessdate = }}</ref> | ||
==References== | ==References== | ||
Latest revision as of 22:25, 2 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]
Adverse Reactions
The most frequent adverse reactions reported during controlled clinical trials were mild, transient burning or stinging upon instillation (4.6%) and palpebral edema (2.8%). Other adverse reactions in decreasing order of reported frequency were superficial punctate keratopathy, epithelial keratopathy, hypersensitivity reaction, stromal edema, irritation, keratitis sicca, hyperemia, and increased intraocular pressure.[1]
References
- ↑ "http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022211s000_sumr.pdf" (PDF). External link in
|title=(help)
Adapted from the FDA Package Insert.